. 2017 Oct 2;26(3):93–100. doi: 10.4274/mirt.94695
©Copyright 2017 by Turkish Society of Nuclear Medicine / Molecular Imaging and Radionuclide Therapy published by Galenos Yayınevi.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 6. Malignancy vs. SUVmax cut-off (Receiver-operating-characteristic).
